

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Canceled)
2. (Currently Amended) ~~The isolated nucleic molecule of claim 1, wherein said~~  
**An isolated nucleic acid molecule comprising a polynucleotide is having SEQ ID NO: 47**  
~~and functional variants thereof~~ **or a functional variant thereof having at least 95%**  
**identity to SEQ ID NO: 47, wherein said polynucleotide and functional variant thereof**  
**confer vascular-preferred polynucleotide transcription.**
3. (Canceled)
4. (Currently Amended) An isolated polynucleotide having a sequence selected  
from
  - (a) sequences complementary to any of the sequences in claim 2; and
  - (b) sequences that are reverse complements to any of the sequences in claim 2,**wherein said sequence is at least 30 nucleotides in length and confers vascular-preferred**  
**polynucleotide transcription.**
5. (Previously Presented) The isolated nucleic molecule of claim 2,  
wherein said polynucleotide confers xylem-preferred gene expression in a plant cell.
6. (Previously Presented) The isolated nucleic molecule of claim 2,  
wherein said polynucleotide is capable of upregulating or downregulating the expression of  
an operably-linked gene in a plant cell.
- 7-20. (Canceled)